相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses
Byron H. Kwan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
cGAS is essential for the antitumor effect of immune checkpoint blockade
Hua Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Immunotherapy-associated autoimmune hemolytic anemia
Uqba Khan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao et al.
NATURE IMMUNOLOGY (2017)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Expanding antigen-specific regulatory networks to treat autoimmunity
Xavier Clemente-Casares et al.
NATURE (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark J. Selby et al.
PLOS ONE (2016)
Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy
Alice Tzeng et al.
CELL REPORTS (2016)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo et al.
CELL (2015)
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Gail D. Sckisel et al.
IMMUNITY (2015)
IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ
Yin Guo et al.
JOURNAL OF IMMUNOLOGY (2015)
Contemporary rends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States
Christopher B. Allard et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication
Yong Liang et al.
SCIENTIFIC REPORTS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Xuanming Yang et al.
CANCER CELL (2014)
Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
Lucas Ferrari de Andrade et al.
CANCER RESEARCH (2014)
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Denise Skrombolas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation
Katia De Filippo et al.
BLOOD (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sylatron: A Pegylated Interferon for Use in Melanoma
Jai N. Patel et al.
ANNALS OF PHARMACOTHERAPY (2012)
IFN-α in the Treatment of Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOLOGY (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo
Hideto Nishikado et al.
JOURNAL OF IMMUNOLOGY (2011)
Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments
Dorothea Busse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes
Kutlu G. Elpek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Initial Phase of an Immune Response Functions to Activate Regulatory T Cells
William E. O'Gorman et al.
JOURNAL OF IMMUNOLOGY (2009)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
Jeremy B. Swann et al.
JOURNAL OF IMMUNOLOGY (2007)
Fifty years of interferon research: Aiming at a moving target
Jan Vilcek
IMMUNITY (2006)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
U Keilholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Monocyte-derived dendritic cells generated after a short-term culture with IFN-α and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response
L Santodonato et al.
JOURNAL OF IMMUNOLOGY (2003)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
MJ Smyth et al.
INTERNATIONAL IMMUNOLOGY (2001)
Kinetics of dendritic cell activation:: impact on priming of TH1, TH2 and nonpolarized T cells
A Langenkamp et al.
NATURE IMMUNOLOGY (2000)
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
